Ocata Therapeutics competitors

Experienced public company CEO determined to leave the world a healthier place than when he arrived by developing new treatments for serious diseases and conditions.

J Scott Wolchko are a President/CEO/COO at FATE THERAPEUTICS INC and Board Member at FATE THERAPEUTICS INC. They have worked as Chief Financial Officer at Bocada and VP:Operations/CFO at FATE THERAPEUTICS INC. J studied at University of Virginia and Alpha Omega Alpha Medical Honor Society.

Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

Dr. Bergstein is Chief Executive Officer and Founder of Stemline Therapeutics. He led Stemline through multiple rounds of private financing and ultimately its successful IPO and subsequent follow-on offering, raising over $100 million as a public company. Prior to founding Stemline, Dr. Bergstein was Medical Director of Access Oncology, Inc., a clinical stage oncology-focused biotechnology company where he was a key member of a small team responsible for the acquisition and development of the company’s clinical stage assets and ultimately the sale of the company. Previously, he was a senior biopharmaceuticals analyst at a Wall Street-based firm that advised mutual funds and hedge funds on investments in public companies with late clinical stage assets. Dr. Bergstein received a B.A. in Mathematics from the University of Pennsylvania. He subsequently earned an M.D. from the Mount Sinai Medical Center where he was named to the Alpha Omega Alpha Medical Honor Society, was recipient of the Merck Award for Clinical Excellence, and subsequently completed a general surgery internship. He was then named the Jerome A. Urban post-doctoral fellow at Cornell University Medical College where he published work concerning oncogenes in breast cancer. Dr. Bergstein then completed a residency in internal medicine and a clinical fellowship in hematology-medical oncology at the New York Presbyterian Hospital-Weill Medical College of Cornell University, where he is currently a voluntary faculty member.

Jason Meyenburg is Chief Executive Officer at Gemini Therapeutics. He has more than 20 years of experience in developing and commercializing therapies for patients with serious conditions. Prior to joining Gemini, Jason served as Chief Commercial Officer at Orchard Therapeutics, a company advancing gene therapies for rare diseases, where he was responsible for building out the global commercial operations. During his tenure at Orchard, the company acquired and integrated the gene therapy portfolio from GSK and launched an IPO of $200 million in 2019. Before Orchard, Jason was Chief Commercial Officer of Vtesse Pharmaceuticals, a company developing a therapy for the rare disease Niemann-Pick C in collaboration with the NIH, and of Sucampo Pharmaceuticals through the acquisition of Vtesse. Before Vtesse and Sucampo, Jason spent 13 years at Alexion Pharmaceuticals in roles of increasing responsibility, including Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas. Jason holds an MBA from Duke University and a B.S. in biochemistry from University of Maryland, College Park.

Technology and Payments EntrepreneurSpecialties: Electronic payments, prepaid, merchant processing both on and offline, global remittance processing, financial services technologies, rent and lease related payments processing, payments compliance, money transfer, mobile money transfer.

Cynthia Bamdad is a CEO at Minerva Biotechnologies and is based in Boston, Massachusetts. She has worked as Director at Pharmacyclics and CSO Clinical Micro Sensors, now Genmark at Minerva Biotechnologies. Cynthia works or has worked as BOARD MEMBER at Schl of Social Science, BOARD MEMBER at Urban Affairs and Public Policy, and BOARD MEMBER at Northeastern University. She attended Harvard University between 1992 and 1997 and Northeastern University.

Mr. Palay is one of our founders and has served as Chairman of the Board and as Chief Executive Officer since 2007. Mr. Palay previously served as chairman of the board and chief executive officer of each of our predecessors from their founding until 2008. He also co-founded NimbleGen Systems, Inc., a molecular biology tools company, and served as its chairman of the board from 1999 to 2007 and as its chief executive officer from 1999 to 2000. Since their inception, Mr. Palay has served as a manager of the general partner or manager of each of the various Tactics II entities, which are private investment vehicles and are among our principal shareholders. He received a A.B., magna cum laude, from Harvard College, an M.M. from the J.L. Kellogg Graduate School of Management and a J.D. from the Northwestern University School of Law. We selected Mr. Palay to serve on our board of directors due to his in-depth understanding of our business and operating experience with business startups.